Rep. Jeff Hurd

Aviation Funding Solvency Act This bill provides continuing appropriations to the Federal Aviation Administration (FAA) if (1) an appropriations bill for the FAA has not been enacted before a fiscal year begins, or (2) a law making continuing appropriations for the FAA is not in effect. Specifically, the bill provides appropriations from the Aviation Insurance Revolving Fund at the rate of operations that was provided for the prior fiscal year to continue programs, projects, and activities that were funded in the preceding fiscal year. The FAA may use the balance of the fund, minus $1 billion. If the FAA determines that the amounts from the fund are insufficient to continue all programs, projects, or activities, then the FAA must prioritize compensation payments for employees of the Air Traffic Organization (e.g., air traffic controllers). The bill provides the appropriations until the date on which either (1) specified appropriations legislation for the fiscal year becomes law, or (2) a bill making continuing appropriations becomes law. Finally, the bill permanently extends the FAA Non-premium War Risk Insurance Program. This program provides aviation insurance without a premium to eligible air carriers at the request of the Department of Defense or another federal agency, provided that the agency agrees to indemnify the FAA from all losses covered under the insurance. Eligible air carriers include those whose operations are under a federal contract and are necessary for national security or to carry out U.S. foreign policy.

Maddy summaryThis bill, titled "Pet and Livestock Protection Act," is misleading; it actually focuses on gray wolf management. It requires the Secretary of the Interior to reissue a 2020 rule removing gray wolves from the endangered species list within 60 days of enactment. The bill also prohibits courts from reviewing this reissuance. This directly affects gray wolf populations and management policies in states where wolves are present, shifting regulatory control away from federal endangered species protections.

Maddy summaryHR 6714, the American Products in Parks Act, requires all items sold in National Park System gift shops and visitor centers to be made in the United States. Specifically, it mandates that final assembly, significant processing, and all or virtually all ingredients/components must originate domestically, effective one year after enactment. The bill directs the Secretary of the Interior to create certification and enforcement procedures to verify compliance. This directly affects park gift shop vendors and suppliers, requiring them to source products domestically to continue selling within national parks.

Maddy summaryThe PERMIT Act (HR 3898) amends the definition of "navigable waters" under the Clean Water Act to exclude specific water features from federal regulation. It explicitly removes waste treatment systems, ephemeral streams (flowing only after rain), prior converted cropland, groundwater, and other features designated by regulators. This change directly affects federal agencies like the EPA and Army Corps of Engineers, reducing their jurisdiction over these excluded water bodies. The bill aims to streamline permitting by clarifying which waters fall under federal Clean Water Act oversight.

Miracle on Ice Congressional Gold Medal Act This act provides for the award of Congressional Gold Medals to the members of the 1980 U.S. Olympic men's ice hockey team in recognition of the team's achievement at the 1980 Winter Olympic Games.

Maddy summaryHR 6575, the CommonGround for Affordable Health Care Act, extends enhanced premium tax credits for health insurance through 2026, directly benefiting millions of lower and middle-income Americans purchasing coverage through the ACA marketplace. The bill modifies income thresholds for premium subsidies, creating new income tiers that maintain or increase financial assistance for households earning up to 1,000% of the poverty level. It includes provisions to prevent fraud in health insurance exchanges by imposing civil penalties on agents and brokers who provide false information, and requires transparency in pharmacy benefit manager contracts to improve drug pricing accountability. The legislation also extends the annual open enrollment period for health insurance exchanges for the 2026 plan year, allowing more time for people to enroll or change coverage.

ePermit Act This bill establishes requirements related to digitizing environmental reviews conducted under the National Environmental Policy Act of 1969 (NEPA). The Council on Environmental Quality (CEQ) must develop, publish, and iteratively update data standards for the collection and curation of certain data related to environmental reviews. CEQ must also design, test, and build prototype tools for environmental reviews. Additionally, CEQ must publish guidance to assist relevant agencies in implementing such standards as well as certain minimum functional requirements, such as data sharing that enables automated transfer of relevant data among federal agencies. Federal agencies responsible for environmental reviews or authorizations must implement the data standards and such minimum functional requirements. To the maximum extent practicable, CEQ and such agencies must iteratively develop and maintain a unified interagency data system consisting of interconnected federal agency systems and shared services for environmental reviews and authorizations, including a common interactive, digital, cloud-based authorization portal. Within a year, CEQ must oversee a pilot of shared services for environmental reviews and authorizations, including the portal. To the maximum extent practicable, CEQ must develop and implement the unified interagency data system by December 1, 2027.

Maddy summaryThe Bipartisan Health Insurance Affordability Act extends and modifies premium tax credit rules to make health insurance more affordable for people with household incomes up to 700% of the poverty line, with specific provisions for different income tiers. The bill requires pharmacy benefit managers to pass through 100% of rebates to health plans, establishes transparency requirements for drug pricing, and creates mechanisms to prevent fraud in health insurance exchanges. It also extends the annual open enrollment period for 2026 and allows qualified Exchange enrollees to establish health savings accounts, with options to prepay annual premiums or direct part of their premium tax credit into a health savings account.

Maddy summaryHR 6540, the "Anti-Communism Week Act," designates an annual observance to commemorate historical impacts of communist regimes. The bill requests the President to annually designate a week as "Anti-Communism Week" and issue a proclamation encouraging public ceremonies. It does not create new policies or affect specific groups; it only adds a procedural requirement to the U.S. Code for an annual presidential designation. The bill focuses on commemoration, not policy change, and references historical findings about communism in its preamble.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)